Navigation Links
B. Braun Renal Therapies Division Announces Availability of Adimea
Date:4/27/2010

BETHLEHEM, Pa., April 27 /PRNewswire/ -- The Renal Therapies Division of B. Braun Medical Inc. (B. Braun) has announced the U.S. introduction of Adimea™, an innovative process for real-time monitoring of dialysis effectiveness during treatment.

(Logo: http://www.newscom.com/cgi-bin/prnh/20081022/NYW008LOGO )

Adimea, developed by B. Braun and already in use in Europe, is designed for use with B. Braun's Dialog+ Hemodialysis System, provides healthcare professionals with the information they need to give patients the optimal dialysis dose (Kt/V).

U.S. FDA-cleared, the Adimea process uses spectroscopy principles to measure dialysis efficiency by determining the reduction in the molar concentration of urinary excreted substances in the spent dialysate by transmitting an ultraviolet (UV) light source through the dialysate. The highly reliable and precise instrument allows the online determination and continual monitoring of current Kt/V values throughout the patient's entire treatment.  

"Adimea is a very important advancement in renal therapies," said Samuel Amory, Vice President, Renal Therapies Division for B. Braun Medical Inc. "It helps healthcare professionals give their patients an optimal dialysis dose and allows them to adjust treatment parameters for the benefit of patients even during treatment."  

Easy to use and efficient, Adimea requires the entry of only one patient parameter R
'/>"/>

SOURCE B. Braun
Copyright©2010 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related medicine technology :

1. B. Braun Medical Inc. to Demonstrate Infusion Systems Technologies at HIMSS 2009 Interoperability Showcase
2. B. Braun Awarded Contract With HealthTrust Purchasing Group to Provide Pain Management Solutions
3. B. Braun and Amerinet Sign to Expand Infusion Therapy Offerings
4. MEDRAD and B. Braun Melsungen AG Collaborate to Promote Breakthrough Medical Treatment for Cardiovascular Disease
5. B. Braun Introduces WHIN(R) Safe Huber Needle
6. B. Braun Infusion Systems Complete Interoperability Test for HIMSS10 Interoperability Showcase
7. Wyeths Torisel and Roche/Genentechs Avastin Will Challenge Pfizers Sutent to Become the Clinical Gold Standard for Treatment of Metastatic Renal Cell Carcinoma
8. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
9. Abbott Initiates Clinical Study to Evaluate Use of RX Herculink(R) Elite(TM) Renal Stent System for the Treatment of Renal Artery Stenosis
10. Interim Phase 2 Data for Exelixis XL880 Show Anti-Tumor Activity in Papillary Renal Cell Cancer
11. EntreMed Shows Increased Survival With MKC-1 in Preclinical Renal Cell Cancer Model
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/18/2013)... SYDNEY, Australia And EMERYVILLE, ... Adamas Pharmaceuticals, Inc. presented final results today from ... HCl extended release) capsules demonstrating a statistically significant ... change from baseline at week 8 versus placebo ... is Adamas, investigational extended-release formulation of amantadine intended ...
(Date:6/17/2013)... LOS ANGELES , June 17, 2013 ... TopProdeals.com , a technology platform that connects buyers ... evolved into being an industry leader. ... scenes at TopProdeals™ are intimately familiar with the dental ... the healthcare community and have diligently worked to negotiate ...
(Date:6/17/2013)... SAN DIEGO , June 17, 2013 BioMed ... that its board of directors has declared a second quarter ... dividend is equivalent to an annualized dividend of $0.94 per ... payable on July 15, 2013 to stockholders of record at ... About BioMed Realty Trust BioMed Realty delivers ...
Breaking Medicine Technology:Adamas Pharmaceuticals Presents Positive Phase 2/3 Results For ADS-5102 For The Treatment Of Levodopa-Induced Dyskinesia (LID) In Parkinson's Disease 2Adamas Pharmaceuticals Presents Positive Phase 2/3 Results For ADS-5102 For The Treatment Of Levodopa-Induced Dyskinesia (LID) In Parkinson's Disease 3Adamas Pharmaceuticals Presents Positive Phase 2/3 Results For ADS-5102 For The Treatment Of Levodopa-Induced Dyskinesia (LID) In Parkinson's Disease 4Adamas Pharmaceuticals Presents Positive Phase 2/3 Results For ADS-5102 For The Treatment Of Levodopa-Induced Dyskinesia (LID) In Parkinson's Disease 5Adamas Pharmaceuticals Presents Positive Phase 2/3 Results For ADS-5102 For The Treatment Of Levodopa-Induced Dyskinesia (LID) In Parkinson's Disease 6TopProdeals.com Rises to Top as Discount Dental Supply Leader 2BioMed Realty Trust Declares Second Quarter 2013 Common Stock Dividend 2BioMed Realty Trust Declares Second Quarter 2013 Common Stock Dividend 3
... WOONSOCKET, R.I., Sept. 19 CVS/pharmacy today,announced that it ... vaccinations in over 4,000 of its stores across the ... on October 1, 2007 and continue,through November. For dates, ... option #1, or visit the CVS.com online Store,Finder to ...
... Targanta Therapeutics Corporation,today released detailed data ... of its lead antibiotic drug candidate, oritavancin, ... of susceptible and resistant strains of,gram- positive ... the 47th,Annual Interscience Conference on Antimicrobial Agents ...
Cached Medicine Technology:CVS/pharmacy Offers Flu Vaccinations in Over 4,000 Stores 2Oritavancin Demonstrates Potent and Rapid In Vitro Activity Against MRSA, VRE and Other Strains of Resistant Bacteria 2Oritavancin Demonstrates Potent and Rapid In Vitro Activity Against MRSA, VRE and Other Strains of Resistant Bacteria 3Oritavancin Demonstrates Potent and Rapid In Vitro Activity Against MRSA, VRE and Other Strains of Resistant Bacteria 4Oritavancin Demonstrates Potent and Rapid In Vitro Activity Against MRSA, VRE and Other Strains of Resistant Bacteria 5
(Date:6/18/2013)... Healthcare Solutions , the parent ... today announced the appointment of Richard Leonardo to ... position, Leonardo will direct Healthcare Solutions’ national sales ... initiatives. , Recognized in the property and casualty ... more than 20 years of experience in business ...
(Date:6/18/2013)... New York, New York (PRWEB) June 18, 2013 ... forward in both state and federal court, a new report ... of more than 70,000 U.S. Food & Drug Administration (FDA) ... According to NewsChannel5 in Cleveland, Ohio, over 4.700 Mirena ... since 2008, while more than 1,300 have reportedly experienced uterine ...
(Date:6/18/2013)... By studying one of the most successful ... of successful strategies in his article What We Can ... Study. , The inspirational brand Gollan refers to is ... an impressive 62 million followers (and rising). , The ... Facebook Pages earlier this year. The Facebook data tracking publication ...
(Date:6/18/2013)... likely to keep their scheduled medical appointments and ... physician listens, explains things clearly and knows them as ... research suggests. , "If people feel their doctor really ... doctor has their best interests at heart and may ... leader Tabor E. Flickinger, M.D., M.P.H., a fellow in ...
(Date:6/18/2013)... research scientist Daniel Perlman has discovered a way to ... foods that are consumed by humans, potentially opening the ... A U.S. patent (#8,460,738) on the new process and ... Phytosterols in plants and cholesterol molecules in animals are ... are attracted to one another. When they mix in ...
Breaking Medicine News(10 mins):Health News:Healthcare Solutions Appoints Richard Leonardo to Chief Sales Officer 2Health News:Mirena Lawsuit News: Bernstein Liebhard LLP Comments on Mounting Reports of Mirena Side Effects, Including Device Migration, Uterine Perforations 2Health News:Mirena Lawsuit News: Bernstein Liebhard LLP Comments on Mounting Reports of Mirena Side Effects, Including Device Migration, Uterine Perforations 3Health News:Casey Gollan Shows What We Can Learn From One of the Best Facebook Pages There Is 2Health News:Casey Gollan Shows What We Can Learn From One of the Best Facebook Pages There Is 3Health News:Respect may be the key to stopping patient 'no shows' 2Health News:Brandeis scientist invents anti-cholesterol process 2
... to identifying high-risk behaviors among adolescents. Injury risk, ... leading causes of adolescent morbidity and mortality; yet pediatricians ... concerns. That paradox of care is the motivation behind ... Pediatrics, which found adolescents who participated in computerized screening ...
... adults and is emerging in the world of pediatrics. A ... D insufficiency, causes rickets in children and can be treated ... as increased sun exposure. , A new study ... the first study to investigate vitamin D insufficiency in pediatric ...
... 1 Aflac Incorporated,announced today that Martin A. Durant ... chief financial officer. Susan R. Blanck has been,promoted to ... are,effective June 1, 2008., Durant first joined Aflac ... He was with Aflac for 10 years, eventually serving ...
... Prenatal biochemical screening tests are widely used to look ... serious handicap, or even death during gestation or in the ... able to detect fewer than half of the total chromosomal ... conference of the European Society of Human Genetics tomorrow (Monday ...
... of particular gene respond well to targeted therapy , , ... who have the normal version of a particular gene ... that includes adding the targeted therapy Erbitux to chemotherapy. ... normal, or "wild-type" form of the gene, according to ...
... melanoma tumors may make the cancer more vulnerable to chemotherapy, ... Duke Comprehensive Cancer Center. , We tested a compound that ... on the surface of a melanoma cell," said Douglas Tyler, ... Medical Center, and senior investigator on this study. "When chemotherapy ...
Cached Medicine News:Health News:Waiting room gadget may prove to be a life-saver 2Health News:First study to examine vitamin D insufficiency in pediatric patients with low bone density 2Health News:Martin Durant Promoted to Executive Vice President and Deputy CFO; Sue Blanck Promoted to First Senior Vice President of Aflac Japan 2Health News:Martin Durant Promoted to Executive Vice President and Deputy CFO; Sue Blanck Promoted to First Senior Vice President of Aflac Japan 3Health News:Prenatal biochemical screening only detects half of chromosomal abnormalities 2Health News:Prenatal biochemical screening only detects half of chromosomal abnormalities 3Health News:Erbitux Works Well for Two-Thirds of Colon Cancer Patients 2Health News:Erbitux Works Well for Two-Thirds of Colon Cancer Patients 3Health News:Combination therapy packs 1-2 punch against melanoma 2
Delicate Desmarres lid retractors, round serrated handle, very thin blades, polished finish, size 1....
2.0 mm cup , straight shaft, Flat handle, length 125.0 mm....
Size 4 - 2.25 mm...
The Storz Protege is an anterior segment unit only....
Medicine Products: